new report $1.47 target...breaking out, page-20

The last enrolled patient is expected to complete dosing in the trial in March 2011. The Company
expects to receive data tables and listings from the trial in June, with the final study report available later
in 2011.
The Company has continued to interact with a number of global pharmaceutical companies throughout
the trial period. It is expected that more detailed commercial discussions will commence in coming
months with a view to securing a licensing transaction for the future development and commercialisation
of XToll?. All interactions are expected to continue for several months.
The Company is progressing a number of activities aimed at reducing the overall development ?time to
market? for XToll?, including local scale-up of the drug manufacturing process, the design of larger
phase IIb/phase III studies as well as pre-IND interactions with the US Food & Drug Administration
(FDA). It is critical that these activities continue apace in order to maximise the commercial potential of
XToll? in the market.